Skip to content
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact
XOMA
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Company & Partner News
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financial Information
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Overview
    • Charts
    • Historical Data
    • IRS Form 8937
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

XOMA to Present New Growth Strategy at the 2017 Wedbush PacGrow Healthcare Conference

Aug 09, 2017 4:30pm EDT

XOMA Reports Second Quarter 2017 Financial Results

Aug 08, 2017 4:30pm EDT

XOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical Development

May 18, 2017 7:00am EDT

XOMA to Present New Strategic Initiatives at the UBS Global Healthcare Conference

May 15, 2017 4:05pm EDT

XOMA Reports First Quarter 2017 Financial Results

May 09, 2017 4:05pm EDT

XOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition

Apr 24, 2017 7:00am EDT

XOMA Presents Positive Data from PTH1R Monoclonal Antibody Program

Apr 18, 2017 7:00am EDT

XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research Annual Meeting

Mar 28, 2017 7:00am EDT

XOMA Announces Four Presentations at the 2017 ENDO Meeting

Mar 23, 2017 7:00am EDT

XOMA Announces Full Repayment of Hercules Technology Growth Capital Debt Obligation

Mar 22, 2017 7:00am EDT
RSS
  • Prev
    • 1...
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • 20
    • ...47
    Next
    • Email Alerts
    • RSS News Feed
    • Terms of Use

    © 2025 XOMA Royalty Corporation.  All rights reserved.

    All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

    • Follow us:
    © 2025 XOMA • Powered by GeneratePress
    Scroll back to top